Diphtheria toxin conjugate therapy of cancer.

Arthur E. Frankel, Bayard L. Powell, Michael B. Lilly

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

The approval by the FDA of ONTAK (DAB389IL2) for CTCL and the encouraging results described above with a number of DT conjugates for different neoplasms suggest that a niche is developing for these biologic agents. Moreover, practicing physicians are becoming more familiar with the side effect profile for these agents, increasing their comfort with using these unique drugs. Finally, the marked synergy observed between standard cytotoxic drugs and other biologics such as Herceptin and Rituximab suggests that similar supra-additive effects may be observed by combining DT conjugates with chemotherapy. In support of this hypothesis, in vitro synergy has been observed between DT388GMCSF and both cytarabine and doxorubicin [84,85]. The future appears to show expanded testing of DT conjugates with likely rapid clinical development, particularly for chemotherapy-resistant hematologic neoplasms and brain tumors.

Original languageEnglish (US)
Pages (from-to)301-313
Number of pages13
JournalCancer chemotherapy and biological response modifiers
Volume20
StatePublished - 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Diphtheria toxin conjugate therapy of cancer.'. Together they form a unique fingerprint.

  • Cite this